Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tamir Shragai

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
European Journal of Haematology|October 26, 2023
Treatment with low-dose, single-agent belantamab mafodotin is safe and provides long-term responses in heavily pretreated multiple myeloma patientsIrit Avivi, Tamir Shragai, Efrat Luttwak, et al.
British Journal of Haematology|August 4, 2020
Characteristics and outcomes of adults with cytomegalovirus-associated thrombocytopenia: a case series and literature reviewTamir Shragai, Eyal Lebel, Dana Deshet, et al.
Blood Advances|March 6, 2025
Clinical outcomes in older adults treated outside clinical studies: highlighting the octogenarian experienceDor Shpitzer, Yael C Cohen, Tamir Shragai, et al.
Cancers|October 16, 2024
The Outcome of Octogenarian Patients with Multiple Myeloma Treated Outside Clinical Studies, Focusing on Tolerability and Efficacy of TreatmentDana Amsterdam, Ori Grossberger, Natan Melamed, et al.
Cancers|May 13, 2026
Histologic Transformation in Follicular Lymphoma: Real-World Outcomes with Rituximab vs. Obinutuzumab-Based CombinationsDor Shpitzer, Chava Perry, Tamir Shragai, et al.
Human Brain Mapping|November 6, 2015
Anatomical and functional connectivity in the default mode network of post-traumatic stress disorder patients after civilian and military-related traumaInbal Reuveni, Omer Bonne, Ruti Giesser, et al.
Cancers|June 13, 2025
Deep-Learning-Based Prediction of t(11;14) in Multiple Myeloma H&E-Stained SamplesNadav Kerner, Dov Hershkovitz, Svetlana Trestman, et al.
Leukemia & Lymphoma|April 16, 2026
Can Belantamab mafodotin cause macro LDH?Leehe Hakakian, Tamir Shragai, Svetlana Trestman, et al.
Acta Haematologica|October 2, 2024
Belantamab Mafodotin in Relapsed/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the LiteratureEyal Lebel, Vladimir Vainstein, Paolo Milani, et al.
Annals of Hematology|August 30, 2023
Management and outcome of 500 multiple myeloma patients treated for first relapse outside clinical studiesIrit Avivi, Naama Yekutiel, Tamir Shragai, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
European Journal of Haematology|October 26, 2023
Treatment with low-dose, single-agent belantamab mafodotin is safe and provides long-term responses in heavily pretreated multiple myeloma patientsIrit Avivi, Tamir Shragai, Efrat Luttwak, et al.
British Journal of Haematology|August 4, 2020
Characteristics and outcomes of adults with cytomegalovirus-associated thrombocytopenia: a case series and literature reviewTamir Shragai, Eyal Lebel, Dana Deshet, et al.
Blood Advances|March 6, 2025
Clinical outcomes in older adults treated outside clinical studies: highlighting the octogenarian experienceDor Shpitzer, Yael C Cohen, Tamir Shragai, et al.
Cancers|October 16, 2024
The Outcome of Octogenarian Patients with Multiple Myeloma Treated Outside Clinical Studies, Focusing on Tolerability and Efficacy of TreatmentDana Amsterdam, Ori Grossberger, Natan Melamed, et al.
Cancers|May 13, 2026
Histologic Transformation in Follicular Lymphoma: Real-World Outcomes with Rituximab vs. Obinutuzumab-Based CombinationsDor Shpitzer, Chava Perry, Tamir Shragai, et al.
Human Brain Mapping|November 6, 2015
Anatomical and functional connectivity in the default mode network of post-traumatic stress disorder patients after civilian and military-related traumaInbal Reuveni, Omer Bonne, Ruti Giesser, et al.
Cancers|June 13, 2025
Deep-Learning-Based Prediction of t(11;14) in Multiple Myeloma H&E-Stained SamplesNadav Kerner, Dov Hershkovitz, Svetlana Trestman, et al.
Leukemia & Lymphoma|April 16, 2026
Can Belantamab mafodotin cause macro LDH?Leehe Hakakian, Tamir Shragai, Svetlana Trestman, et al.
Acta Haematologica|October 2, 2024
Belantamab Mafodotin in Relapsed/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the LiteratureEyal Lebel, Vladimir Vainstein, Paolo Milani, et al.
Annals of Hematology|August 30, 2023
Management and outcome of 500 multiple myeloma patients treated for first relapse outside clinical studiesIrit Avivi, Naama Yekutiel, Tamir Shragai, et al.
Pageof 2